

Neurotech International | Provisional Patent Lodgements

- **NTI lodges two strategic provisional patent applications to underpin future world-wide patent families. Provisional patent applications will assist in current strategic partner negotiations regarding the potential commercial rollout of low THC (<0.3%), full spectrum cannabinoid products.**
- **Extensive preclinical studies have led to novel findings in relation to the compositional profile and the unique efficacy of NTI-164 currently being used in NTI's Phase I/II ASD clinical trial at Monash Children's Hospital.**
- **The two provisional patents have been lodged to cover (1) the uniqueness of the strain - composition profile with low THC (<0.3%) and a unique combination of 'rarer' cannabinoids, and (2) the application and use of the strain in relation to the treatment of a broad range of neuro-inflammatory disorders both on its own and in conjunction with current broadly available treatment options - 'combination treatment therapies'.**

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to announce that it has filed its first strategic provisional patent applications with IP Australia to underpin future world-wide patent families in respect to research conducted into the novel neuro-regulatory and anti-inflammatory properties of the NTI/Dolce medicinal cannabis strains. The two patents have been lodged to cover:

1. Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) and a unique combination of 'rarer' cannabinoids, and;
2. The application, formulation and use of the strain in relation to the treatment of a broad range of neuro-inflammatory disorders both on its own and in conjunction with current broadly available treatment options - 'combination treatment therapies'.

Pre-clinical testing to date has demonstrated efficacy with regards to the use of NTI-164 in combination with diclofenac, to provide a complementary and synergistic activity. Key identified advantages include increased efficacy with lower dosage requirements, which may lead to a reduction in side effects of taking certain anti-inflammatory pharmaceutical drugs.

The patent position allows NTI to explore opportunities to expand the use of its novel cannabis strain into nutraceutical, over the counter and pharmaceutical markets providing multiple opportunities for strategic partners and the ability to utilise the clinical data generated for multiple commercialisation applications. NTI will continue to generate preclinical and clinical data to further strengthen its patent position. The company will continue to expand the use and application of the novel strains to complex neuro-inflammatory disorders.

The 'composition patent' relates to a unique composition of six identified cannabinoids with low THC (<0.3%). In combination, the cannabinoids have shown to suppress COX-2, IL2 and TNF-alpha molecules that are largely responsible for inflammation and pain in the human body. As previously announced, the ability to suppress these specific inflammatory molecules differs significantly from standard CBD isolate. Studies to date have demonstrated that NTI-164 can uniquely impact

inflammatory processes outside of the endocannabinoid system and is the subject of the composition patent.

The 'combination patent' invention relates to the NTI-164 strain used in combination with an additional active ingredient (already being used to treat specific ailments). The invention also relates to pharmaceutical compositions, dosage forms and methods of treating neurological disorders by administering the composition to a patient.

Preclinical studies currently being undertaken are investigating three common pharmaceutically available drugs that potentially improve in performance (eg. anti-inflammatory effects) when used in combination with NTI-164. Importantly, standard dosage of the pharmaceutical drugs can be significantly reduced when tested in combination with NTI-164.

Given the well documented side effects of anti-inflammatory pharmaceutical drugs, the possibility of creating treatments that reduce dosage and increase efficacy has enabled NTI to file the provisional patent applications and move to finalise current in vitro tests as a matter of priority and commence further Phase II trials.

Neurotech's Chairman, Mr Brian Leedman said:

"We are delighted with the lodging of two provisional patent applications that we have achieved in a little over 12 months of research to underpin future world-wide patent families for our key cannabinoid strain in respect of both composition and combination therapies with existing pharmaceutical treatments. The patent applications will assist in current strategic partner discussions regarding commercialisation pathways. The ability to utilise our low THC strain with unique neuro-regulatory and anti-inflammatory properties is enabling NTI to ramp up pre-clinical work as we complete our Phase I/II clinical trial of ASD in children with results expected to be released next month. Final preclinical results in MS will be released in coming weeks in respect of NTI-164 used in combination with additional actives."

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Brian Leedman
Chairman
b.leedman@neurotechinternational.com
+61 (0)41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 (0)41 066 7844

Media:

Juliana Roadley
IR Department
juliana.roadley@irdepartment.com.au
+61 (0)41 488 9863

About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>